The CureWorks collaborative model will be unconstrained by the status quo, which we believe will lead to more cures in less time, with less risk for all involved.
Our goal is to deliver effective and safe immunotherapies to patients earlier in their treatment cycle. Aggregating diverse data from trials will help us increase our overall understanding and accelerate our rate of progress. This approach maximizes the number of potential candidates to present for FDA review and approval and, ultimately, the therapies CureWorks is able to provide to our patients.
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD19+ Acute Leukemia | Seattle Children's | Active NCT02028455 |
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD 19+ Acute Leukemia | Seattle Children's' | Active NCT03186118 |
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19+ T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD22+ Leukemia | Seattle Children's | Enrollment Pause | Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia and Lymphoma |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD19+CD22+ Leukemia and Lymphoma | Seattle Children's, Children's National Health System | Active NCT03330691 |
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T Cell Immunotherapy for CD19+CD22+ Leukemia |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| CD19+ Acute Leukemia | Seattle Children's' | Active NCT03684889 |
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| EGFR+ (m806 epitope) Recurrent / Refractory solid tumors | Seattle Children's | Active NCT03618381 |
Phase 1 Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| B7H3+ Recurrent / Refractory solid tumors | Seattle Children's | In Preparation |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| EGFR+ (m806 epitope) Recurrent / Refractory solid tumors | Seattle Children's | Active NCT03618381 |
Phase 1 Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| EGFR+ (m806 epitope) Recurrent / Refractory Central Nervous System (CNS) tumors | Seattle Children's | Active NCT03638167 |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| B7H3+ Recurrent / Refractory Central Nervous System (CNS) tumors | Seattle Children's | In Preparation |
| TARGET | INSTITUTION | TRIAL INFO | OFFICIAL TITLE |
|---|---|---|---|
| L1-CAM+ Recurrent / Refractory Neuroblastoma | Seattle Children's | Active NCT02311621 |
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma using Autologous T-cells lentivirally transduced to express CD171-specific Chimeric Antigen Receptors |